Valencia Technologies to Present at Canaccord Genuity Medical Technologies & Diagnostics Forum

NEW YORK, Nov. 9, 2017 /PRNewswire/ -- Founder and CEO of Valencia Technologies Corp. ("Valencia"), Jeff Greiner, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum at 8am on November 9, 2017 at the Westin Grand Central in New York City.

Founded in 2011, Valencia has designed, developed, manufactured and clinically tested a nickel-sized and shaped neurostimulator for the treatment of various chronic conditions.  The focus of Greiner's discussion will be on the Company's overactive bladder application for its tiny bioelectronic implant called "eCoin^TM". 

Having obtained an Investigational Device Exemption (IDE) from FDA earlier this year, Valencia has implanted 46 patients in the United States and New Zealand in its feasibility study on overactive bladder with urge incontinence.  

Greiner will discuss the business, technology, and preliminary results from its trial.  "eCoin^TM will change the way overactive bladder is treated," Greiner explains, "because it is minimally invasive, has no side effects, is relatively low cost, and may be superior in efficacy to all others."  While
preliminary, the results in patients out two and three months are exceptional. The Company is currently planning its pivotal trial to begin next year.

About Valencia

Valencia Technologies Corporation is a medical technology company located in Valencia, California.  Valencia has created a coin-sized bioelectronic implant for the treatment of overactive bladder, hypertension, and other chronic conditions.  Implanted in the lower leg during a 20-minute office or outpatient procedure, eCoin^TM for OAB will be tested in a pivotal trial in 2018.

About eCoin^TM for OAB

eCoin^TM for OAB is a fully implantable neurostimulator the size and shape of a US nickel.  eCoin^TM is implanted in the left or right lower leg where it stimulates the tibial nerve.  Based on percutaneous tibial nerve stimulation, eCoin^TM is the first known fully-implantable neurostimulator developed and tested in a clinical setting.  Other implantable devices targeting the tibial nerve are externally powered. 

For more information on Valencia, please visit the website: www.valenciatechnologies.com.

Contact: Stacy Chambliss
Email: [email protected]

SOURCE Valencia Technologies Corporation